Compare SCM & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCM | ALXO |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.3M | 205.9M |
| IPO Year | 2012 | 2020 |
| Metric | SCM | ALXO |
|---|---|---|
| Price | $8.41 | $2.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $9.00 | $3.50 |
| AVG Volume (30 Days) | 286.6K | ★ 626.9K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 14.22% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $141.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.83 | $0.60 |
| 52 Week High | $14.85 | $2.66 |
| Indicator | SCM | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 61.74 | 57.76 |
| Support Level | $7.93 | $1.96 |
| Resistance Level | $8.59 | $2.31 |
| Average True Range (ATR) | 0.35 | 0.14 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 97.60 | 89.66 |
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.